Evidence map›Paper›PMID 39942729›Full record

ReviewMolecules (Basel, Switzerland)2025

Light-Activable Silver Nanoparticles for Combatting Antibiotic-Resistant Bacteria and Biofilms.

Varsha Godakhindi, Elana Kravitz, Juan Luis Vivero-Escoto

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Biosynthesis and Characterization ofNanomaterials (Basel, Switzerland) · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Chitosan-silver nanocomposites: promising alternatives for combating azole-resistantFrontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Varsha GodakhindiDepartment of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Elana KravitzDepartment of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Juan Luis Vivero-EscotoDepartment of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.

Funding

Light-Activated Silver Nanoparticles to Eliminate Antibiotic Resistant Bacteria and GenesR16GM145434 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · PI VIVERO-ESCOTO, JUAN LUIS · 2022 to 2024
$509k
NIGMS NIH HHS R16 GM145434NIH HHS R16GM145434
6 · The paper itself

Abstract

Silver nanoparticles (AgNPs) are among the most widely used nanoparticulate materials for antimicrobial applications. The innate antibacterial properties of AgNPs are closely associated with the release of silver ions (Ag

Indexed as

Anti-Bacterial AgentsBacteriaBiofilmsDrug Resistance, BacterialLightMetal NanoparticlesSilverHumansMicrobial Sensitivity TestsPhotosensitizing AgentsReactive Oxygen SpeciesAnti-Bacterial AgentsPhotosensitizing AgentsReactive Oxygen SpeciesSilverantibiofilm agentslight activated antibacterialsphotodynamic inactivationphotosensitizerssilver nanoparticles

Identifiers

PMID39942729
PMCPMC11819709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.